The'purpose of the Histopathology Facility (HF) is to facilitate research conducted by funded investigators at Fox Chase Cancer Center (FCCC) by providing histology and pathology services including processing of cells and tissues as well as helping in the interpretation of results. The Facility's Technicians and Pathologist play a major support role in numerous research projects at the Center and their contributions have been, and continue to be of great significance in the establishment and characterization of animal models of human cancer. The Facility prepares, processes, and assists in evaluating tissues derived from experimental protocols developed by peer-reviewed, funded investigators. Most of the projects involve animal models of human cancer that require complex histological and/or cytological processing to determine morphological alterations, as well as to localize cancer-relevant gene products. The most frequently utilized services of the Facility during 2005-2009 include: laboratory animal autopsy, fixation, embedding and sectioning of paraffin-embedded tissue blocks (8,000-12,000 per year), unstained paraffin sections for immunohistochemistry (IHC) and laser capture microdissection (LCM) (9,000-14,000 per year), cryomicrotomy (200-1,500 per year), special stains (200-500 per year), immunohistochemistry (IHC) (2,100-3,700 per year), digital microphotography (3,000-5,000 per year), and interpretative histopathology (7,000- 10,000 H&E and IHC slides signed-out per year). During the last CCSG funding cycle we have seen a steady need for all services rendered and significant increase (100%) in the number of frozen sections performed. Furthermore, during 2005-2010 we consolidated new technology such as the web-based Experimental Histopathology database and introduced computerized image analysis. The HF also provides support to the Laboratory Animal Facility (LAF) in quality control and animal health monitoring activities, as well as processing support to the Biosample Repository Facility (BRF) and the LCM component of the Genomics Facility (GF). The HF was used by 39 peer-reviewed, funded investigators in all five Research Programs at FCCC, in calendar year 2009.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Research Institute of Fox Chase Cancer Center
United States
Zip Code
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1280 publications